A novel agent targeting APRIL: A new hope for elderly patients of IgA nephropathy
Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and neutralizes the activity of APRIL. It should usher in a new era in the treatment of IgAN, especially in elderly patients.
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Aging Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/agm2.12370 |